Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Solid Tumors 1Neoplasms 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Has results × birinapant × Clear all
NCT02587962 2021-01-14

Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors

Medivir

Phase 1/2 Terminated
34 enrolled 27 charts
Other solid neoplasm

Solid Tumors

NCT01188499 2016-05-30

Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors

TetraLogic Pharmaceuticals

Phase 1/2 Completed
176 enrolled 13 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡